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INTRODUCTION
Brain tumors are divided into primary brain tumors,
which originate from the brain itself, andmetastatic
brain tumors, which originate from the tumors of
other bodyparts. According to theWorldHealthOr-
ganization (WHO) grading system, primary brain tu-
mors are classified as low-grade tumors (grade I–II)
and high-grade tumors (grade III–IV). Furthermore,
the most common metastatic brain tumors
originate from the breast, lung, and skin (mela-
noma).1 Among the high grade gliomas, there is dif-
ferentiation based on origin of the tumor, such as
secondary high grade gliomas are transformed
from lower grade gliomas. On the other hand, pri-
mary glioblastomas commonly do not have a pre-
cursor lesion.2 Among primary brain gliomas,
glioblastoma (GBM) is the most frequent and
most lethal primary brain tumor.
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KEY POINTS
 Theranostic nuclear oncology, mainly in neuro-oncology (neurotheranostics), aims to combine can-
cer imaging and therapy using the same molecular targeting platform.
 The ability of radioneurotheranostic agents to interact with cancer cells at the molecular level with
high specificity can significantly improve the effectiveness of cancer therapy and helps to identify
patients who are most likely to benefit from tumor molecular radionuclide therapy.
 A variety of biologic targets are under investigation for treating brain tumors.
 PET-based precision imaging can substantially improve the therapeutic efficacy of radiotheranostic
approach in brain tumors.
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